Mayo Investment Advisers LLC lifted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 11.2% in the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 91,253 shares of the biopharmaceutical company’s stock after buying an additional 9,180 shares during the quarter. Gilead Sciences comprises 2.6% of Mayo Investment Advisers LLC’s holdings, making the stock its 19th biggest position. Mayo Investment Advisers LLC’s holdings in Gilead Sciences were worth $6,459,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Schroder Investment Management Group lifted its holdings in shares of Gilead Sciences by 12.8% during the second quarter. Schroder Investment Management Group now owns 4,096,640 shares of the biopharmaceutical company’s stock worth $290,288,000 after buying an additional 464,576 shares in the last quarter. Old Mutual Global Investors UK Ltd. lifted its holdings in shares of Gilead Sciences by 131.7% during the second quarter. Old Mutual Global Investors UK Ltd. now owns 260,188 shares of the biopharmaceutical company’s stock worth $18,416,000 after buying an additional 147,911 shares in the last quarter. IFM Investors Pty Ltd increased its position in shares of Gilead Sciences by 110.6% in the second quarter. IFM Investors Pty Ltd now owns 35,879 shares of the biopharmaceutical company’s stock worth $2,540,000 after purchasing an additional 18,846 shares during the period. Freestone Capital Holdings LLC increased its position in shares of Gilead Sciences by 2.2% in the second quarter. Freestone Capital Holdings LLC now owns 282,543 shares of the biopharmaceutical company’s stock worth $19,998,000 after purchasing an additional 6,027 shares during the period. Finally, Bienville Capital Management LLC increased its position in shares of Gilead Sciences by 18.3% in the second quarter. Bienville Capital Management LLC now owns 9,925 shares of the biopharmaceutical company’s stock worth $702,000 after purchasing an additional 1,535 shares during the period. 74.62% of the stock is owned by institutional investors.
TRADEMARK VIOLATION NOTICE: This article was originally posted by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this article on another domain, it was stolen and republished in violation of United States and international copyright and trademark law. The original version of this article can be read at https://sportsperspectives.com/2017/11/15/mayo-investment-advisers-llc-boosts-stake-in-gilead-sciences-inc-gild.html.
A number of brokerages recently commented on GILD. Argus cut Gilead Sciences from a “buy” rating to a “hold” rating and raised their price target for the stock from $73.25 to $73.77 in a research report on Monday. Mizuho raised their price target on Gilead Sciences from $77.00 to $83.00 and gave the stock a “buy” rating in a research report on Wednesday, November 8th. Maxim Group restated a “hold” rating on shares of Gilead Sciences in a research report on Friday, October 27th. BMO Capital Markets decreased their price target on Gilead Sciences from $89.00 to $83.00 and set an “outperform” rating on the stock in a research report on Friday, October 27th. Finally, J P Morgan Chase & Co set a $85.00 price target on Gilead Sciences and gave the stock a “buy” rating in a research report on Wednesday, October 25th. One investment analyst has rated the stock with a sell rating, twelve have issued a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $84.87.
Gilead Sciences, Inc. (NASDAQ GILD) opened at $71.15 on Wednesday. Gilead Sciences, Inc. has a 12 month low of $63.76 and a 12 month high of $86.27. The company has a quick ratio of 3.56, a current ratio of 3.68 and a debt-to-equity ratio of 1.10. The stock has a market capitalization of $92,920.00, a P/E ratio of 7.60, a price-to-earnings-growth ratio of -1.22 and a beta of 1.13.
Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.13 by $0.14. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The firm had revenue of $6.51 billion for the quarter, compared to analyst estimates of $6.40 billion. During the same period in the previous year, the firm earned $2.75 earnings per share. The company’s revenue was down 13.2% compared to the same quarter last year. equities research analysts anticipate that Gilead Sciences, Inc. will post 8.53 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 28th. Shareholders of record on Friday, December 15th will be paid a $0.52 dividend. This represents a $2.08 annualized dividend and a yield of 2.92%. The ex-dividend date is Thursday, December 14th. Gilead Sciences’s dividend payout ratio (DPR) is presently 23.66%.
In other news, EVP James R. Meyers sold 60,000 shares of the business’s stock in a transaction that occurred on Thursday, August 31st. The stock was sold at an average price of $83.19, for a total transaction of $4,991,400.00. Following the completion of the sale, the executive vice president now owns 62,715 shares in the company, valued at $5,217,260.85. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Gregg H. Alton sold 50,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 30th. The shares were sold at an average price of $79.00, for a total value of $3,950,000.00. Following the sale, the executive vice president now owns 113,237 shares of the company’s stock, valued at approximately $8,945,723. The disclosure for this sale can be found here. Over the last three months, insiders sold 446,819 shares of company stock worth $36,269,486. Insiders own 1.30% of the company’s stock.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.